Study of GS-0272 in Participants With Rheumatoid Arthritis

Stopped early · Phase 1 · Has a placebo group

Conditions studied: Rheumatoid Arthritis

In brief

The goals of this clinical study are to learn more about the study drug, GS-0272, and its safety and tolerability following multiple doses in participants with rheumatoid arthritis (RA). The primary objectives of this study are to assess the safety and tolerability of multiple ascending doses of GS-0272 and to characterize the pharmacokinetics of GS-0272 following multiple doses of GS-0272, in participants with RA.

Key facts

Study ID
NCT06031415
Run by
Gilead Sciences
People needed
55
Starts
2023-09-28
Expected to finish
2026-05-11
Last updated by the study team
2026-05-27

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.